What Weatherden does

Weatherden is a private, for-profit clinical development consulting group headquartered in London, United Kingdom, founded in 2017. The firm positions itself as serving clients in the clinical development lifecycle, a domain that typically encompasses translational planning, clinical trial design, regulatory strategy, and program execution support for biopharma and biotech sponsors. Its leadership comprises Emma Tinsley as Chief Executive Officer and Houman Ashrafian as Chairman of the Board, suggesting a senior-led consulting model rather than a technology-platform model.

The company's operating footprint is concentrated in London, with reported headcount in the 11–50 employee range, consistent with a boutique professional services firm. No detailed product, technology, pricing, or service-line disclosures are present in the supplied source material; the primary website (weatherden.co.uk) returned only a verification/loading page at the time of capture and contributed no additional operational detail. Consequently, the specific service mix, delivery model, and underlying tooling cannot be substantiated from the available data.

Based on the available evidence, Weatherden's business model appears to be fee-for-service consulting revenue from pharmaceutical, biotech, or academic clinical development clients, though no customer list, contract values, or revenue figures are disclosed. There is no public record of funding rounds, partnerships, awards, certifications, or M&A activity in the input. The investment-relevant takeaway is that Weatherden is a small, privately held UK clinical consulting boutique with limited publicly verifiable scale or differentiation data; further diligence on client base, utilization, and senior consultant bench would be required to substantiate any growth or valuation thesis.

Name

Weatherden

Website

https://weatherden.co.uk

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Weatherden is a London-based clinical development consulting group founded in 2017, serving biopharma and biotech clients with small-scale (11–50 employees) advisory support across the clinical development lifecycle.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Core offering

Weatherden is a London-based clinical development consulting group that provides advisory and consulting services to pharmaceutical and biotechnology companies. The firm supports clients across drug development programs, helping navigate clinical strategy, trial design, and regulatory pathways. It operates as a specialized consultancy rather than a software or product vendor.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Development Consulting Advisory and consulting services supporting pharmaceutical and biotechnology sponsors across clinical development strategy, trial design, and regulatory planning. Intended for drug development teams within pharma and biotech organizations.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights1 record

Broad incumbents

• IQVIA: IQVIA is the world's largest CRO with deep clinical development consulting, real-world evidence, and technology-enabled development services. Comparable to Weatherden as the dominant end-to-end incumbent that increasingly absorbs boutique-style clinical advisory work into its R&D Solutions umbrella.
• ICON plc: ICON plc is a global CRO with substantial clinical development consulting and strategic advisory services post-PRA Health Sciences. Comparable to Weatherden as a top-tier incumbent offering both operational trial delivery and clinical development advisory, often competing for the same biotech sponsor engagements.
• Parexel International: Parexel is a large global CRO with deep clinical development consulting across biostatistics, regulatory, and clinical strategy. Comparable to Weatherden as a scaled incumbent whose consulting arms overlap directly with boutique specialists serving biotech and mid-cap pharma sponsors.
• Medpace: Medpace is a mid-to-large CRO with embedded medical and clinical development advisory focused on biotech and small-to-mid pharma. Comparable to Weatherden in sponsor segment focus and clinical development advisory depth, but operating at substantially larger scale.
• Charles River Laboratories: Charles River Laboratories is a large CRO/CDMO with a meaningful clinical development consulting offering alongside preclinical and manufacturing services. Comparable to Weatherden in the consulting function, though Charles River operates at significantly greater scale and breadth across the drug development value chain.
• Syneos Health (now part of Elliott/Veritas): Syneos Health is a global biopharma solutions organization combining CRO and commercial services with embedded clinical development advisory. Comparable to Weatherden at the incumbent end of the clinical consulting market, frequently bidding against specialists for biotech development engagements.

Direct peers

• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized global CRO offering full-service clinical development plus scientific and regulatory consulting to biotech and pharma sponsors. Comparable to Weatherden as a more concentrated peer in clinical development advisory, with overlapping biotech sponsor focus and similar positioning between boutique and tier-1 CROs.
• CTI Clinical Trial and Consulting Services: CTI Clinical Trial and Consulting Services is a privately held CRO combining clinical operations with biostatistics, regulatory, and consulting services, especially in rare disease and oncology. Comparable to Weatherden as a mid-sized peer operating clinical development consulting alongside operational delivery, more often to smaller biotech sponsors.
• Catalyst Clinical Research: Catalyst Clinical Research is an independent mid-sized CRO with specialty clinical development consulting across oncology, rare disease, and cell/gene therapy. Comparable to Weatherden as an independent peer with combined operational delivery and consulting, similar in size profile and biotech sponsor emphasis.
• Precision Medicine Group: Precision Medicine Group is a specialty clinical development and biomarker services provider with embedded consulting across clinical strategy, biostatistics, and regulatory. Comparable to Weatherden as a focused clinical development services specialist serving biotech and emerging pharma, often competing for similar niche engagements.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Weatherden